Nivolumab (anti-PD-1) | 946414-94-4 | BMS-936558 | ONO-4538

規(guī)格	庫(kù)存	目錄價(jià)	會(huì)員專享價(jià)	數(shù)量
1 mg	3-5days	￥2000.00	登錄后可見(jiàn)	- +
5 mg	3-5days	￥7500.00	登錄后可見(jiàn)	- +
10 mg	3-5days	￥12000.00	登錄后可見(jiàn)	- +
50 mg	3-5days	￥28000.00	登錄后可見(jiàn)	- +
100 mg	3-5days	￥45600.00	登錄后可見(jiàn)	- +

規(guī)格

庫(kù)存

目錄價(jià)

會(huì)員專享價(jià)

數(shù)量

1 mg

3-5days

￥2000.00

登錄后可見(jiàn)

- +

5 mg

3-5days

￥7500.00

登錄后可見(jiàn)

- +

10 mg

3-5days

￥12000.00

登錄后可見(jiàn)

- +

50 mg

3-5days

￥28000.00

登錄后可見(jiàn)

- +

100 mg

3-5days

￥45600.00

登錄后可見(jiàn)

- +

基本信息

英文名稱	Nivolumab (anti-PD-1) (Synonyms:BMS-936558; ONO-4538; MDX-1106)
中文名稱	納武單抗 (anti-PD-1); 尼魯單抗
CAS號(hào)	946414-94-4
分子量	143599.09
外觀	Colorless to light yellow liquid
儲(chǔ)存條件	Sealed and stored at ≤-80℃, away from light. Avoid freeze-thaw cycles

產(chǎn)品詳情

1.Nivolumab (anti-PD-1) is a genetically engineered, fully human immunoglobulin (Ig) G4 monoclonal antibody directed against the negative immunoregulatory human cell surface receptor programmed death-1 (PD-1,PCD-1) with immune checkpoint inhibitory and antineoplastic activities. MW : 143.597 KD.

2.Nivolumab is a programmed death receptor-1 (PD-1) blocking human IgG4 antibody to treat advanced (metastatic) non-small cell lung cancer.

相關(guān)文獻(xiàn)

抱歉，暫時(shí)沒(méi)有相關(guān)文獻(xiàn)

相關(guān)產(chǎn)品

抱歉，暫時(shí)沒(méi)有相關(guān)產(chǎn)品

瀏覽記錄

CLA1002

納武單抗 (anti-PD-1); 尼魯單抗

946414-94-4 95+% 3-5days

￥2000.00 1 mg

久久久无码视频,影音先锋女人av噜噜色,久久久久无码国产精品Sm高潮,人人色综合

納武單抗 (anti-PD-1); 尼魯單抗

Nivolumab (anti-PD-1) (Synonyms:BMS-936558; ONO-4538; MDX-1106)

化學(xué)品安全說(shuō)明書(shū)(MSDS)

質(zhì)檢證書(shū)(COA)